Cell signalling pathways, driven by protein kinases are involved in the onset and progression of virtually all cancer types. As of 2021, 89 kinase inhibitor drugs have been approved, with over 150 in clinical trials and thousands in the preclinical stages.
Kinomica’s services in Oncology drug development deliver identification of targets, mode of action studies, off-target effects, drug resistance mechanisms and improved patient stratification for Clinical Trials.
Talk to our Experts
To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.
If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.
“We can help scientists to understand more accurately where their drugs can have the most efficacious impact, reducing costs and speeding development, and we can help clinicians identify which drug will work most effectively in a patient target group”
Anthony Sullivan, Business Development Director